

# CANTO - Chronic toxicities in patients with early breast cancer

Head :Andre Fabrice, Inserm U981

Last update : 01/18/2013 | Version : 1 | ID : 3082

## General

### Identification

Detailed name Chronic toxicities in patients with early breast cancer

Sign or acronym CANTO

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation N° CPP : 11.039 N° AFSSAPS : B111158-20

### General Aspects

Medical area Cancer research

Health determinants Genetic  
Iatrogenic

Others (details) breast cancer

Keywords adversed effects, long term toxicity, financial impact, predictors for chronic toxicity, toxicity, psychological impact, social impact, biomarkers

### Scientific investigator(s) (Contact)

Name of the director Andre

Surname Fabrice

Address 114 rue Edouard Vaillant 94805 Villejuif

Email fabrice.andre@inserm.fr

Unit Inserm U981

Organization Institut Gustave Roussy

### Collaborations

### Funding

Funding status Mixed

Details ANR "Investissements d'avenir -Grand emprunt", Biomérieux, INCA,

### Governance of the database

Sponsor(s) or organisation(s) responsible Institut Gustave Roussy (IGR)

Organisation status Public

Sponsor(s) or organisation(s) responsible Fédération Nationale des centres de lutte contre le Cancer

Organisation status Public

### Additional contact

### Main features

### Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is made on the basis of: Medication(s) taken

Database recruitment is carried out as part of an interventional study No

### Database objective

Main objective The primary goal will be to generate predictors of chronic toxicity in patients with early breast cancer treated with anticancer agents. This project will include four specific aims:

- To develop a database of chronic toxicity in a cohort of 20 000 women with stage I-III breast cancer
- To describe incidence, clinical presentation, biological characteristics and outcome of chronic toxicities
- To describe the psychosocial and economic impact of chronic toxicities
- To generate predictors for chronic toxicities

Inclusion criteria	Women with non-metastatic breast cancer (I to III stade) treated in one of the 10 medical centers involved in the study
<b>Population type</b>	
Age	Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Woman
Geography area	National
Detail of the geography area	France territory
<b>Data collection</b>	
<b>Dates</b>	
Date of first collection (YYYY or MM/YYYY)	2012
<b>Size of the database</b>	
Size of the database (number of individuals)	[10 000-20 000[ individuals
Details of the number of individuals	20 000
<b>Data</b>	
Database activity	Current data collection
Type of data collected	Clinical data Declarative data Paraclinical data
Clinical data (detail)	Direct physical measures
Declarative data (detail)	Paper self-questionnaire
Paraclinical data (detail)	Heart US, MRI joint, electromyogram, bone densitometry, Uterine US
Presence of a biobank	Yes
Contents of biobank	Whole blood

Details of biobank content	whole blood
Health parameters studied	Health event/morbidity
<b>Procedures</b>	
Data collection method	Inclusion: each women will fill a first questionnaire for demographics and living conditions, and a set of validated questionnaires related to QoL (BR 23) and special psychological dimensions. MDs will fill the questionnaire
Participant monitoring	Yes
Links to administrative sources	No
<b>Promotion and access</b>	
<b>Promotion</b>	
<b>Access</b>	
Terms of data access (charter for data provision, format of data, availability delay)	Ask the person in charge
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only